Oscar Health Inc Stock Price, News & Analysis

Oscar Health (NYSE:OSCR) has announced plans to offer $350 million in convertible senior subordinated notes due 2030, with an additional option for purchasers to buy up to $52.5 million in notes. The offering aims to support general corporate purposes, including AI initiatives, healthcare cost reduction, and enhanced consumer experiences.

The notes will be convertible to cash, class A common stock, or a combination thereof. To mitigate potential dilution, Oscar will enter into capped call transactions. The company plans to terminate its existing revolving credit facility upon the offering's closing. The notes will be redeemable after September 6, 2028, if Oscar's stock price exceeds 130% of the conversion price for a specified period.

Oscar Health (NYSE:OSCR) and Hy-Vee have announced a strategic partnership to launch Hy-Vee Health with Oscar, an innovative employer healthcare benefit program. The initiative will debut in Des Moines, Iowa, targeting approximately 400,000 employees through the individual marketplace starting November 1, 2025.

The program offers significant cost savings, with businesses potentially saving 20% to 30% and employees saving $500 to $1,000 annually. Key benefits include $0 care at Hy-Vee Health Exemplar Care clinics, access to MercyOne specialists, affordable prescriptions at Hy-Vee pharmacies, dedicated Oscar Care Guides, and Hy-Vee rewards for grocery savings.

Oscar Health (NYSE:OSCR) reported its Q2 2025 financial results, showing significant revenue growth but facing profitability challenges. Total revenue reached $2.9 billion, up from $2.2 billion in Q2 2024, driven by increased membership to 2.02 million members.

The company reported a net loss of $228.4 million ($0.89 per share) compared to a net income of $56.2 million in Q2 2024. The medical loss ratio increased to 91.1% from 79.0%, while the SG&A expense ratio improved to 18.7% from 19.6%. Management expects market stabilization in 2026 and anticipates a return to profitability, viewing the individual market as having long-term growth potential.

Oscar Health (NYSE:OSCR) released preliminary Q2 2025 results and revised its 2025 guidance downward. The company expects a Q2 2025 operating loss of $230 million and a net loss of $228 million. The revision follows analysis of 2025 Marketplace data showing higher-than-expected ACA Marketplace risk scores.

For full year 2025, Oscar now projects total revenue of $12.0-12.2 billion, a medical loss ratio of 86.0-87.0%, and an SG&A expense ratio of 17.1-17.6%. The company anticipates a loss from operations between $300 million and $200 million. In response, Oscar plans to resubmit 2026 rate filings for approximately 98% of current membership to reflect higher market risk scores.

Oscar Health reported robust Q1 2025 financial results with significant growth across key metrics. Total revenue surged 42% year-over-year to $3.0 billion, driven by increased membership. Net income reached $275.3 million ($0.92 per diluted share), up from $177.4 million in Q1 2024. The company's total membership grew to 2.04 million, primarily in Individual and Small Group segments. Operating efficiency improved with SG&A ratio decreasing to 15.8% from 18.4%, while medical loss ratio slightly increased to 75.4%. Adjusted EBITDA rose to $328.8 million, reflecting strong operational performance. The company reaffirmed its full-year 2025 guidance across all metrics.

Oscar Health (NYSE: OSCR), a healthcare technology company, has scheduled its first quarter 2025 financial results release and earnings conference call. The company will announce Q1 2025 results before market opening on Wednesday, May 7, 2025, followed by a management conference call at 8:00 AM ET.

Investors can access the call via phone at 1.855.761.5600 (Conference ID: 7768132) or through webcast. The call recording will be available on Oscar's investor relations website (ir.hioscar.com) for 90 days after the event.

Ataraxis AI has secured a $20.4 million Series A financing round led by AIX Ventures, with participation from notable investors including Peter Thiel and former Oscar Health (NYSE: OSCR) CEO Mario Schlosser. The company's AI foundation model, Kestrel, powers their first product Ataraxis Breast, which has shown to be 30% more accurate than current breast cancer care standards in clinical validation.

The platform is set to launch for clinical use across the United States later this year. The funding will support expanding treatment selection capabilities within and beyond breast cancer. The company has formed a Clinical Advisory Board featuring oncology leaders from top health systems, including experts from Northwell Lenox Hill, Yale Cancer Center, UPMC Hillman Cancer Center, and NYU.

Oscar Health (NYSE: OSCR) reported its strongest financial performance in company history for 2024, achieving profitability for the first time. Total revenue reached $9.2 billion, up 56.5% year-over-year, driven by membership growth during Open Enrollment and Special Enrollment Period additions.

Key financial metrics include a Medical Loss Ratio of 81.7% (10 bps increase YoY), SG&A Expense Ratio of 19.1% (520 bps improvement YoY), and net income of $25.4 million ($0.10 per diluted share). Adjusted EBITDA was $199.2 million, improving by $244.5 million YoY.

For 2025, Oscar projects revenue between $11.2-11.3 billion, Medical Loss Ratio of 80.7-81.7%, and SG&A Expense Ratio of 17.6-18.1%. The company also announced Janet Liang will join as President of Oscar Health Insurance on February 24, 2025.

Oscar Health (NYSE: OSCR) announced it will release its fourth quarter and full year 2024 financial results after market close on Tuesday, February 4, 2025. The healthcare technology company will host a conference call at 5:00 PM ET on the same day to discuss the results. Investors can access the call via phone (1.855.761.5600, Conference ID: 7768132) or webcast. The call recording will be available on Oscar's investor relations website for 90 days following the event.